Testing glofitamab plus polatuzumab for high-risk diffuse lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed CD20-positive diffuse large B-cell lymphoma (DLBCL), not previously treated (except limited steroid use or up to one cycle of R-CHOP).
- Your lymphoma type fits specific categories of aggressive/related B-cell lymphomas, as judged by the study team.
- You can provide usable tumor tissue from before starting (archived within 90 days) or you must have a new biopsy during screening.
- Your scan shows at least one measurable lymphoma spot on PET/CT (FDG-avid) measuring more than 1.5 cm.
- Your overall health scores are within limits: age 18+, and you can still do daily activities at level 0–2 (ECOG). Your heart and blood counts also must meet thresholds (including heart pumping strength ≥50%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
This trial tests a new combination of three targeted drugs as the first treatment for aggressive B-cell lymphomas. The goal is to see if this approach can effectively treat the lymphoma and reduce the need for standard chemotherapy.
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
This trial tests a new combination therapy using glofitamab for people aged 65 or older with diffuse large B-cell lymphoma who have not received prior treatment. The goal is to see if this approach is safe and effective for patients who are considered too frail for standard therapies.
This trial tests a combination of two targeted drugs, polatuzumab vedotin and glofitamab, for people with large B-cell lymphoma that came back or didn't go away after their first standard treatment. The goal is to see if this combination can help control the lymphoma.
This trial tests a new combination of drugs (glofitamab plus GemOx) against the usual treatment for people whose diffuse large B-cell lymphoma (a type of blood cancer) has returned or not gone away after initial therapy. The goal is to see if this new approach works better and helps you live longer.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.